Classement en actions
#36618
Lysogene S.A. is a biopharmaceutical firm specializing in gene therapy,... Lysogene S.A. is a biopharmaceutical firm specializing in gene therapy, dedicated to discovering and advancing treatments for children affected by severe neurodegenerative lysosomal storage disorders. Its development pipeline includes LYS-SAF302, which is currently undergoing Phase II/III clinical trials for mucopolysaccharidosis type IIIA (MPS IIIA). Another promising candidate, LYS-GM101, is in Phase I/II development, targeting GM1 gangliosidosis. The company has also forged a research alliance with the Weizmann Institute of Science to pioneer novel adeno-associated virus (AAV) gene therapy approaches for conditions such as neuronopathic Gaucher disease, Parkinson's disease, and other related illnesses. Lysogene S.A. was established in 2009 and is headquartered in Neuilly-sur-Seine, France.
Prix de l'action
$0.30221445
Dernière synchronisation: 2023-05-22
Capitalisation boursière
$2.49M
Changement (1 jour)
-0.10%
Échange Lysogene S.A. (LYS)
Le prix LYS avec la capitalisation boursière de B
Capitalisation boursière de Lysogene S.A.(LYS)
Capitalisation boursière: $2.49M
En August 2026, Lysogene S.A. a une capitalisation boursière de $2.49M. Cela fait de Lysogene S.A. la 36618th entreprise la plus valorisée au monde selon nos données. La capitalisation boursière, souvent appelée market cap, correspond à la valeur totale des actions en circulation d’une entreprise cotée en bourse, et est couramment utilisée pour évaluer sa valeur.
Historique de la capitalisation boursière de Lysogene S.A. du 2017 au 2026
LYS par rapport au top 5 des plus populaires stocks
| Prix pour LYS |
|
L’actif B |
La capitalisation boursière de B |
Résultats |
|
|
|
|
$5.452T
|
+218,595,217.06%
|
|
|
|
|
$4.490T
|
+180,029,466.10%
|
|
|
|
|
$4.162T
|
+166,893,655.77%
|
|
|
|
|
$3.676T
|
+147,404,657.49%
|
|
|
|
|
$2.833T
|
+113,592,136.88%
|
